| Literature DB >> 23316249 |
V A Varney1, A Warner, A Ghosh, A Nicholas, N Sumar.
Abstract
Circulating angiotensin-II protects the circulation against sudden falls in blood pressure and is generated by the enzymatic action of angiotensin converting enzyme (ACE) on angiotensin-I. The ACE genes have 2 allelic forms, "I" and "D." The "D" genotype has both highest angiotensin-II generation and serum ACE levels compared to "I". 120 patients with IgE-anaphylaxis, 119 healthy controls, and 49 atopics had serum ACE levels, ACE genotype, and renin levels determined. Plasma renin levels were identical for all groups. Serum ACE levels and genotypes were similar for healthy controls (HC) and atopics, but lower in anaphylaxis (P = 0.012), with ACE genotypes also showing increased "I" genes (P = 0.009). This effect was more pronounced in subjects manifesting airway angioedema and cardiovascular collapse (AACVS) than mild cutaneous and respiratory (CRA) symptoms. AACVS was significantly associated with the presence of "I" genes. For "ID" genotype OR is 5.6, 95% CI 1.8 to 17.4, and for "II" genotype OR is 44, 95% CI 5 to 1891 within the anaphylaxis group = 0.001. The results show a difference in the genotype frequency between control and anaphylaxis, suggesting a role for the renin angiotensin system in anaphylaxis manifesting with airway angioedema and cardiovascular collapse.Entities:
Year: 2012 PMID: 23316249 PMCID: PMC3536050 DOI: 10.1155/2012/258145
Source DB: PubMed Journal: J Allergy (Cairo) ISSN: 1687-9783
Figure 1Schematic diagram of important interactions of renin angiotensin system.
Demographics of study groups.
| Subject groups | Mean age (range) | % Female | Allergen sensitivity number of cases | Grades 1–4 (no. of cases) |
|---|---|---|---|---|
| Healthy controls | 53 (25–71) | 73 | ||
|
| ||||
| Atopic controls | 47 (18–77) | 79 | Fish 2 | |
|
| ||||
| Anaphylaxis | 45 (16–71) | 65 | Venom 44 | Grades (G) |
Check list used for conventional anaphylaxic symptoms Grades 1–4.
| Anaphylaxis grades | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| Hypotension | Faint/dizzy | Unconscious | Prolonged unconsciousness | Cardiac Arrest |
| Bronchospasm | Wheezy | Severe | Poor response to treatment | |
| Angioedema | Lips/face | Generalised | Severe | |
| Airway oedema | Hoarse | Difficulty in swallowing | difficulty in breathing | |
| Urticaria | Mild | General | severe | |
| Pruritus | Mild | Severe | ||
| Conjunctivitis | Mild | Severe | Ulcerated | |
| Vomiting | Once | Severe | Prolonged | |
| Diarrhoea | Once | Severe | Prolonged | |
| Abdominal | pains | Severe cramps | Bleeding | |
| CNS | Describe all |
Serum ACE levels for the study groups.
| Subject groups | Mean serum |
|
|
|
|---|---|---|---|---|
| Healthy controls | 48.9 ± 25 | 0.53 | 0.012 (3.4, 27.9) | |
| Atopic controls | 47.9 ± 25 | 0.86 | 0.018 (−16.1, −1.5) | |
| Anaphylaxis | 33.2 ± 20 | 0.012 (3.4, 27.9) | 0.018 (−16.1, −1.5) | |
| CRA* | 35.1 ± 25 | 0.031 (1.14, 24.3) | 0.025 (1.6, 25.9) | 0.23 |
|
AACVS+
| 31.2 ± 20 | 0.015 (1.72, 15.5) | 0.011 (2.2, 17.1) | 0.81 |
*Cutaneous and respiratory allergy.
+Acute angioedema and cardiovascular collapse.
ACE genotype frequency for the groups and anaphylaxis grades.
| ACE genotype | DD | ID | II | Healthy controls | Atopics | Anaphylaxis | Cutaneous and RS |
|---|---|---|---|---|---|---|---|
| Healthy controls (HC) | 53 (45%) | 44 (37%) | 22 (18%) |
|
|
| |
| Atopic controls | 15 (31%) | 26 (53%) | 8 (16%) |
|
|
| |
| Anaphylaxis | 30 (25%) | 58 (50%) | 32 (25%) |
|
| ||
| Cutaneous & respiratory anaphylaxis | 15 (56%) | 12 (44%) | 0 (0%) |
|
| ||
| Airway angioedema ± CVS collapse | 15 (16%) | 46 (49%) | 32 (35%) |
|
|
| |
|
| |||||||
| Traditional grades of anaphylaxis | DD | ID | II | Grade 1 | Grade 2 | Grade 3 | |
|
| |||||||
| Grade 1 | 4 (40%) | 5 (50%) | 1 (10%) |
|
| ||
| Grade 2 | 9 (17%) | 25 (46%) | 20 (37%) |
|
| ||
| Grade 3 | 16 (31%) | 26 (51%) | 9 (18%) |
|
| ||
| Grade 4 | 1 (20%) | 2 (40%) | 2 (40%) |
|
|
| |
Odds ratio analysis of genotype comparison with DD genotype.
| Comparisons with DD | Odds ratio (95% CI) | Odds ratio (95%CI) | Chi square |
|---|---|---|---|
| ID | II | ||
| Relative to healthy controls ( | |||
| Atopies ( | 2.3 (1.0–5.4) | 1.4 (0.4–4.1) | 0.082 |
| Anaphylaxis ( | 3.3 (1.7–6.3) | 3.1 (1.4–6.9) | <0.001 |
| CRA ( | 1.1 (0.4–2.9) | 0 (0–0.7) | 0.051 |
| AACVS ( | 6.3 (2.7–15.3) | 7.5 (2.9–19.8) | <0.001 |
|
| |||
| Relative to atopic subjects ( | |||
| Anaphylaxis ( | 1.4 (0.6–3.3) | 2.3 (0.7–7.3) | 0.24 |
| CRA ( | 0.5 (0.2–1.5) | 0 (0–0.5) | 0.028 |
| AACVS ( | 2.7 (1.0–7.7) | 5.4 (1.5–19.5) | 0.009 |
|
| |||
| Relative to CRA ( | |||
| AACVS ( | 5.6 (1.8–17.4) | 44 (5–1891)* | <0.001 |
*calculated by adding 1 to each cell, biased towards 1.